Material Event (Form 8-K)

Item 8.01 Other Events.

On September 19, 2025, BioCardia, Inc. (the "Company") consummated the sale of 4,800,000 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), and accompanying warrants to purchase up to 4,800,000 shares of Common Stock (the "Warrants" and, together with such shares of Common Stock, the "Securities"), at a combined offering price of $1.25 per share and Warrant pursuant to securities purchase agreements (the "Purchase Agreements") by and between the Company and certain purchasers and pursuant to the Company's Registration Statement (No. 333-290283) on Form S-1, declared effective by the Securities and Exchange Commission on September 18, 2025 (such offering, the "Offering"). Certain of the Company's directors and executive officers purchased an aggregate of 734,400 shares of Common Stock and accompanying Warrants, representing gross proceeds of approximately $0.9 million in the Offering. The expected net proceeds to the Company from the Offering were $5.1 million after deducting placement agent fees and other offering expenses. Each Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions.

In addition, under the Purchase Agreements, the Company agreed to, subject to certain exceptions, not issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the prospectus or a prospectus supplement in connection with the at-the-market offering, and a registration statement on Form S-8), through November 18, 2025. H.C. Wainwright & Co., LLC, the placement agent in the Offering (the "Placement Agent"), may waive the terms of this lock-up agreement in its sole discretion and without notice. The Company also agreed not to effect or enter into an agreement to effect any issuance by it or its subsidiaries of any securities that involve a variable rate transaction (as defined in the Purchase Agreement) through March 19, 2026, subject to certain exceptions, such as the entry into and/or issuance of shares of Common Stock in an "at the market" offering with the Placement Agent as sales agent after November 18, 2025. The Placement Agent may waive this prohibition in its sole discretion and without notice.

Each Warrant is exercisable at a price per share of $1.25. The Warrants expire on September 20, 2027. Each Warrant is immediately exercisable. The exercise price of the Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, stock combinations, reorganizations or similar events affecting the Common Stock. Subject to limited exceptions, a holder of Warrants will not have the right to exercise any portion of its Warrants if the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or any of such holder's affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any Warrants, 9.99%) of the shares of common stock then outstanding. At the holder's option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days' prior notice to the Company.

The forms of Warrant, and Purchase Agreement are filed as Exhibits 4.1 and 99.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The above descriptions of the terms of the Warrants and Purchase Agreement are qualified in their entirety by reference to such exhibits.